Skip to main content

Table 1 Patient baseline characteristics

From: Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

  All patients
(n = 50) Missing
Sex
 Male (%) 34 (68.0)  
 Female (%) 16 (32.0)
Age (y)
 Median (range) 69 (41–83)  
ECOG PS
 0 (%) 13 (26.0) 2 (4.0)
 1 (%) 31 (62.0)
  ≥ 2 (%) 4 (8.0)
Prior surgical resection 25 (50.0)  
Tumor location
 Head (%) 24 (48.0)  
 Body-Tail (%) 26 (52.0)
Tumor size (cm)
 Median (range) 4.5 (2.0–18.0) 1 (2.0)
Extent of disease
 Locally advanced (%) 6 (12.0)  
 Metastatic (%) 44 (88.0)
Measurable metastatic sites
 Liver (%) 26 (52.0)  
 Lymph node (%) 20 (40.0)
 Lung (%) 4 (8.0)
 Peritoneal (%) 12 (24.0)
LDH, U/L
 Median (range) 205 (128–909) 2 (4.0)
CRP, mg/L
 Median (range) 13 (0–178) 2 (4.0)
CEA, ng/mL
 Median (range) 3.0 (0.7–64.1) 1 (2.0)
CA19–9, U/mL
 Median (range) 35.7 (1.0–43,645) 1 (2.0)
Histological subtype
 Anaplastic type (%) 16 (32.0)  
 Sarcomatoid type (%) 4 (8.0)
 Undifferentiated carcinoma with OGCs (%) 11 (22.0)
 NOS (%) 19 (38.0)
  1. ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, OGCs osteoclast-like giant cells, NOS not otherwise specified